Pfizer Inc. (PFE)

36.46
0.00 (0.00)
NYSE : Health Technology
Prev Close 36.46
Open 36.65
Day Low/High 36.36 / 36.68
52 Wk Low/High 33.97 / 46.47
Volume 12.58M
Avg Volume 23.92M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 201.66B
EPS 1.90
P/E Ratio 16.42
Div & Yield 1.44 (3.89%)
Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.

Pfizer Completes Acquisition Of Array Biopharma

Pfizer Completes Acquisition Of Array Biopharma

Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

NEW YORK, July 29, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Pfizer reports earnings and announces a massive tie-up with Mylan, sending shares of the latter shooting higher.

A Look at Mylan's New Post-Merger Management

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

It's Market Madness: Jim Cramer on Earnings Season, Pfizer and Mylan, Starbucks

It's Market Madness: Jim Cramer on Earnings Season, Pfizer and Mylan, Starbucks

Jim Cramer weighs in on Pfizer and Mylan, Starbucks and, of course, the causes for a week of market madness.

Pfizer to Combine Off-Patent Drug Division With Mylan

Pfizer to Combine Off-Patent Drug Division With Mylan

Mylan and Pfizer agreed to combine their off-patent drug businesses in an all-stock deal that will create a new company based in the United States.

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Pfizer is in talks to merge its off-patent drug operation with Mylan.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.

Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call To July 29, 2019 At 10:30 A.m. EDT

Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call To July 29, 2019 At 10:30 A.m. EDT

Due to today's announcement of a proposed transaction between Pfizer and Mylan, Pfizer's second-quarter 2019 earnings conference call with investment analysts has been rescheduled for today, July 29, 2019, at 10:30 a.

PFIZER REPORTS SECOND-QUARTER 2019 RESULTS 

PFIZER REPORTS SECOND-QUARTER 2019 RESULTS 

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2019 and updated certain components of its 2019 financial guidance.

Mylan And Upjohn, A Division Of Pfizer, To Combine, Creating A New Champion For Global Health Uniquely Positioned To Fulfill The World's Need For Medicine

Mylan And Upjohn, A Division Of Pfizer, To Combine, Creating A New Champion For Global Health Uniquely Positioned To Fulfill The World's Need For Medicine

- Delivers enhanced global scale and geographic reach, including leading positions in China and other emerging markets

Mylan Shares Surge Amid Reports of Off-Patent Drug Combination with Pfizer

Mylan Shares Surge Amid Reports of Off-Patent Drug Combination with Pfizer

Mylan shares were indicated sharply higher Monday amid reports the generic drugs group is set to create a separate business with Pfizer for off-patent pharmaceuticals.

Pfizer, Mylan Plan to Combine Generic Drug Business: Reports

Pfizer, Mylan Plan to Combine Generic Drug Business: Reports

Shareholders of Mylan would get around 40% of the newly formed business and Pfizer shareholders would get the remaining 60%, according to Reuters.

Go-Go Growth: Cramer's 'Mad Money' Recap (Tuesday 7/23/19)

Go-Go Growth: Cramer's 'Mad Money' Recap (Tuesday 7/23/19)

Jim Cramer says higher sales, higher prices, and demand from emerging markets seem to be fueling a return to the days of great senior growth stocks.

Pfizer, eBay, Cloudera: 'Mad Money' Lightning Round

Pfizer, eBay, Cloudera: 'Mad Money' Lightning Round

Jim Cramer weighs in on Pfizer, eBay, Cloudera, Cadence Systems, CRISPR Therapeutics, Moderna, Tandem Diabetes Care, and more.

Jim Cramer: It's Looking Like the 1980s

Jim Cramer: It's Looking Like the 1980s

Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.

FDA Approves Pfizer's Biosimilar, RUXIENCE™ (rituximab-pvvr), For Certain Cancers And Autoimmune Conditions

FDA Approves Pfizer's Biosimilar, RUXIENCE™ (rituximab-pvvr), For Certain Cancers And Autoimmune Conditions

Pfizer Inc. (NYSE:PFE) today announced the United States (U.

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

Sangamo Shares Soar as Hemophilia Drug Shows Promise

Sangamo Shares Soar as Hemophilia Drug Shows Promise

Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.

Sangamo And Pfizer Announce Updated Phase 1/2 Results For SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Sangamo And Pfizer Announce Updated Phase 1/2 Results For SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

TheStreet Quant Rating: B (Buy)